182 related articles for article (PubMed ID: 38353722)
41. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
42. Cost-Effectiveness Analysis of MammaPrint
Luyendijk M; Jager A; Buijs SM; Siesling S; Groot CAU; Blommestein HM
Pharmacoeconomics; 2023 Aug; 41(8):981-997. PubMed ID: 37245167
[TBL] [Abstract][Full Text] [Related]
43. Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income.
Ursem CJ; Bosworth HB; Shelby RA; Hwang W; Anderson RT; Kimmick GG
J Womens Health (Larchmt); 2015 May; 24(5):403-8. PubMed ID: 25884292
[TBL] [Abstract][Full Text] [Related]
44. "It is not just any pill"-Women's experiences of endocrine therapy after breast cancer surgery.
Ahlstedt Karlsson S; Wallengren C; Olofsson Bagge R; Henoch I
Eur J Cancer Care (Engl); 2019 May; 28(3):e13009. PubMed ID: 30748038
[TBL] [Abstract][Full Text] [Related]
45. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
46. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer.
Adachi Y; Oze I; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Sugino K; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Takatsuka D; Iwata H
Breast Cancer; 2021 Sep; 28(5):1087-1095. PubMed ID: 33886077
[TBL] [Abstract][Full Text] [Related]
47. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
[TBL] [Abstract][Full Text] [Related]
48. Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
Lipsyc-Sharf M; Ballman KV; Campbell JD; Muss HB; Perez EA; Shulman LN; Carey LA; Partridge AH; Warner ET
JAMA Netw Open; 2023 Oct; 6(10):e2339584. PubMed ID: 37878313
[TBL] [Abstract][Full Text] [Related]
49. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer update.
Kuter I
Oncologist; 2000; 5(4):285-92. PubMed ID: 10964995
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study.
Joseph K; Zebak S; Alba V; Mah K; Au C; Vos L; Ghosh S; Abraham A; Chafe S; Wiebe E; Liu HW; Chambers C; Gabos Z; Tankel K; Lupichuk S; King K
Radiother Oncol; 2021 Jan; 154():93-100. PubMed ID: 32941956
[TBL] [Abstract][Full Text] [Related]
52. Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
Stabellini N; Cao L; Towe CW; Amin AL; Montero AJ
Cancer Med; 2023 Oct; 12(19):19607-19616. PubMed ID: 37766666
[TBL] [Abstract][Full Text] [Related]
53. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
[TBL] [Abstract][Full Text] [Related]
54. Precision medicine in extended adjuvant endocrine therapy for breast cancer.
Tesch ME
Curr Opin Oncol; 2023 Nov; 35(6):453-460. PubMed ID: 37621168
[TBL] [Abstract][Full Text] [Related]
55. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Zhao Y; Li Y; Gong C; Xie Y; Zhang J; Wang L; Cao J; Tao Z; Wang B; Hu X
Cancer Med; 2020 Dec; 9(23):8821-8831. PubMed ID: 33022852
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
Paridaens RJ; Gelber S; Cole BF; Gelber RD; Thürlimann B; Price KN; Holmberg SB; Crivellari D; Coates AS; Goldhirsch A
Breast Cancer Res Treat; 2010 Aug; 123(1):303-10. PubMed ID: 20195744
[TBL] [Abstract][Full Text] [Related]
57. Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy.
Feldman-Stewart D; Madarnas Y; Mates M; Tong C; Grunfeld E; Verma S; Carolan H; Brundage M
Breast; 2013 Oct; 22(5):919-25. PubMed ID: 23721853
[TBL] [Abstract][Full Text] [Related]
58. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE
JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030
[TBL] [Abstract][Full Text] [Related]
59. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
Hind D; Wyld L; Beverley CB; Reed MW
Cochrane Database Syst Rev; 2006 Jan; (1):CD004272. PubMed ID: 16437480
[TBL] [Abstract][Full Text] [Related]
60. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
